Pathogenese und neue Therapieansätze beim systemischen Lupus erythematosus
Pathogenese und neue Therapieansätze beim systemischen Lupus erythematosus
复制标题
DOI：
10.1007/s00393-014-1399-7
复制
发表时间：
2014-12-07
影响因子：
1.000
通讯作者：
K. Tenbrock
中科院分区：
文献类型：
--
作者：
K. Tenbrock
系统性红斑狼疮是一种复杂的自身免疫性疾病，可影响多个器官，其特征在于对核抗原的外周耐受性丧失、致病性B和T细胞应答以及自身抗体的产生。据估计，欧洲人口中的患病率为每100 000人40例，但非洲-加勒比人口中的患病率可高达每100 000人150例。虽然20世纪50年代的5年生存率估计仅为50%，但目前估计10年生存率为70- 92%。这一进展尤其是由于对发病机制的更好理解，在过去开辟了更好的治疗可能性，现在为未来的治疗方法提出了新的观点。这导致由于将来疾病负担的减少而预期患者预后的改善。几种新的治疗药物目前正在等待批准，最近50多年来首次批准了一种用于SLE的新药，一种肿瘤坏死因子（TNF）样配体的单克隆抗体，属于TNF家族的B细胞活化因子（BAFF），也称为B细胞淋巴细胞刺激因子（BLyS），BAFF/BLyS。
Systemic lupus erythematosus is a complex autoimmune disease that can affect multiple organs and is characterized by a loss of peripheral tolerance against nuclear antigens, pathogenic B and T cell responses and production of autoantibodies. The prevalence is estimated to be 40 per 100,000 in the population in Europe but can be as high as 150 patients per 100,000 among the Afro-Caribbean population. Although the 5-year survival rate in the 1950s was estimated to be only 50 %, the 10-year survival rate is currently estimated to be 70–92 %. This progress is particularly due to a better understanding of the pathogenesis that opened up better therapeutic possibilities in the past and now raises new perspectives for future therapy approaches.The current knowledge on the pathogenesis and the current situation of new therapeutic approaches for SLE are presented.This progress in the therapeutic options was made possible by a better understanding of the pathophysiology, which leads to the expectation of an improvement in the prognosis of patients due to reduction in the burden of the disease in the future. Several new therapeutic medications are currently awaiting approval and recently for the first time in more than 50 years a new medication for SLE was approved, a monoclonal antibody to the tumor necrosis factor (TNF)-like ligand, B-cell activating factor (BAFF) belonging to the TNF family also named B-cell lymphocyte stimulator (BLyS), BAFF/BLyS.